Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Adverse events occurring in 10% of patients or more in the pivotal study of single-agent rituximab in relapsed andrefractory indolent lymphoma

From: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

  Number of patients  
Adverse event Grade 1/2 Grade 3 Grade 4 %
Fever 84 - - 43
Chills 51 2 - 28
Nausea 34 1 - 18
Headache 26 1 - 14
Angio-oedema 27 1 - 14
Asthenia 25 - - 13
Pruritus 21 1 - 13
Pain 22 - - 11
Rash 16 - - 10
Hypotension 18 1 - 10
Anaemia 1 1 - 10
  1. From McLaughlin and coworkers [13]. Reprinted with permission from the American Society of Clinical Oncology.